External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASH 2024

We will be contributing to topics related to
-
01:30 AM
Duration 2hrs San Diego, USA
Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated With Crovalimab or Eculizumab
Kulasekararaj A.G, Czyz J, Roncone Gastal G, Vannucchi A.M, Viigimaa l, Flynn C, Ando K, Hus M, Belén Vidriales M, Lalagianni E, Seabra P, Nur E, Scheinberg P, Röth A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:30 PM
Duration 15mins Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4
Health Equity Impacts of Funding Emicizumab in People With Severe Hemophilia A in the US: an Aggregate Distributional Cost-Effectiveness Analysis
Thomas Majda, Janet Lee, Randall Curtis, Stacey Kowal
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 AM
Duration 2hrs San Diego, USA
Phase Ill Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
Phillip Scheinberg, Diego Villa Clé, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jorg Schubert, Kazutaka Sunami, Mustafa N. Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G. Kulasekararaj
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Preclinical evaluation of NXT007 using in vitro and in vivo models of hemostasis and thrombosis
Locke M, Albiez JJ, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Best practices to overcoming challenges in initiating venetoclax for patients with chronic lymphocytic leukemia: results from a United States community-based healthcare practitioner survey
Jacobs R, Fletcher L, Rettew A, Li SS, Eakle K, Shahkarami M, Wang R, To TM, Mathias SD, Manigault I, Burke J
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
Mead-Harvey C, Noble BN, Yee C, Mazza GL, Langlais B, Patel S, Trask P, Rogak L, Basch E, Dueck AC, Thanarajasingam G
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase III CRISTALLO Trial
Sportoletti P, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Boyer M, Jiang Y, Cazares O, Morschhauser F, Sharman JP
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Primary results of the health-related quality of life (HRQoL) and tolerability assessments from the Phase I/II NP30179 study of glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
Bachy E, Trask P, Morschhauser F, Corradini P, Wu S-J, Bartlett N, Mulvihill E, Bene Tchaleu F, Lundberg L, Carlo-Stella C
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Characterizing the US patient population receiving rituximab with gemcitabine and oxaliplatin (R-GemOx) for relapsed or refractory diffuse large B-cell lymphoma using real-world data
Budde LE, Olszewski AJ, Hu B, Shah N, Batlevi CL, Yin S, To I, Wei MC, Kallemeijn MJ, Orellana-Noia V, Musick L, Shamas N, Pal N, Shewade A, Westin J
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Glofitamab induces high response rates and durable remissions in patients with heavily pretreated relapsed/refractory mantle cell lymphoma , including those with a poor prognosis: subgroup results from a Phase I/II study
Phillips T, Trněnỳ M, Carlo-Stella C, Zaucha J, Wrobel T, Offner F, Dickinson M, Tani M, Crump M, Bartlett NL, Martinez-Lopez J, Corradini P, Mulvihill E, Bottos A, Kaufman D, Relf J, Bene Tchaleu F, Bazeos A, Lundberg L, Morschhauser F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Bleed patterns in infants, from birth to 12 months of age, with hemophilia A treated with emicizumab: exploratory analysis of the HAVEN 7 study
Carpenter SL, Rosenfelt D, Tzeng E, Lim E, Pipe SW
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Subcutaneous mosunetuzumab leads to high rates of durable responses, low rates of cytokine release syndrome, and non-inferior exposure compared with intravenous administration in patients with relapsed/refractory follicular lymphoma: primary analysis of a pivotal Phase II study
Bartlett NL, Sehn LH, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Kwan A, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory mantle cell lymphoma
Budde LE, Matasar M, Sehn LH, Assouline S, Kuruvilla J, Flinn IW, Yoon SS, Bosch F, Greenwald D, Gutierrez NC, Tzachanis D, Marlton P, McGuirt D, Yin S, Wei MC, Kwan A, Tracy S, Penuel E, Bartlett NL
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
Advani R, Dickinson M, Fox CP, Kahl B, Herrera AF, Lenz G, Song Y, Tao R, Cai Q, Kim TM, Doral M, Kaufman D, Pereira LR, Berthier A, Morschhauser F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:30 PM
Duration 15mins Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
Salles G, Morschhauser F, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Song Y, Pinto A, Rai S, Izutsu K, Lee C, Chohan S, Sugidono M, Jiang Y, Batlevi CL, Yan M, Hirata J, Tilly H, Flowers CR
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:00 PM
Duration 15mins San Diego Convention Center, Ballroom 20AB
Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
Diefenbach C, Zelenetz AD, Herbaux C, Tani M, Houot R, Bastos-Oreiro M, Tilly H, Gastinne T, Thieblemont C, Leung W, Hatzi K, Kesavan M, Boyer M, Morschhauser F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:45 AM
Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17
CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Korfi K, Wilson S, Jiang Z, Christiansen A, Krishnan S, Jamois C, Leung W, Sam J, Blank A, Prieto I, Silva A, Knuckles P, Epp A, Hayward J, Lechner K, Dimier N, Caimi P, Falchi L, Gritti G, Morschhauser F, Hutchings M, Dickinson M, Carlo-Stella C
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:00 AM
Duration 2hrs San Diego, USA
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Roth A, He G, Brodsky A, Chai-Adisaksopha C, Comia N.S, Kori A.N, Höglund M, J. Kelly R, Lee J, Dwilewicz Trojaczek J, Obara N, Risitano A, Gaya A, Han B
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database
Amy Shapiro, Robert Schuldt, Zhiyu Xia, Carmen Ng, Lucy Lee, Juliana Biondo, Janet Lee
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
A Healthcare Utilization Model Comparing Time Toxicity Between Glofitamab and Epcoritamab Treatment Regimens
Torka P, Masaquel A, Cassoli L, Fox D, Ravelo A, Major A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: updated results from the Phase II MorningSun study
Burke JM, Flinn IW, Budde LE, Tun AM, Liu S, Biondo JML, Jani P, Wu M, Mun Y, Chopra VS, Grindheim JM, Farinella D, Villasboas JC
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutations
Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Boyer M, Jiang Y, Cazares O, Morschhauser F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
An economic analysis assessing the budget impact of introducing glofitamab with gemcitabine and oxaliplatin for autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma to a United States health plan
Fox D, Rosettie KL, El Moustaid F, Masaquel A, Cassoli L, Flowers CR
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Evaluation of anti-tumor activity and impact on T-cell activation of glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx)
Bacac M, Sam J, Kim WS, Gregory GP, Ku M, Herter S, Klein C, Umana P, Simko S, Orellana-Noia V, Lundberg L, Bottos A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
FVIII exposure analysis from the HAVEN 7 study of emicizumab in infants with severe hemophilia A
Young G, Eakle K, Lim E, Wang M
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Venetoclax may overcome the prognostic disadvantage of short telomere length regarding progression free survival in elderly CLL treated: a cooperation of the German CLL Study Group (GCLLSG) with the study group for aplastic anemia and bone marrow failure syndromes
Frenzel LP, Beckmann L, Robrecht S, Zhang C, Al-Sawaf O, Stilgenbauer S, Runkel ED, Jiang Y, Brümmendorf T, Hallek M, Eichhorst B, Fischer K, Beier F, Isfort S
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1min San Diego, USA
BP43131, a Phase 1 dose escalation study : CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
Dickinson M, Hutchings M, Morschhauser F, Carlo-Stella C, Falchi L, Caimi P, Dimier N, Smith L, Whayman M, Sam J, Keelara A, Korfi K, Jamois C, Gallien J, Martin N, Martinez-Quetglas I, Hinton H, Prieto I, Michielin F, Lechner K, Gritti G
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-line Chronic Lymphocytic Leukemia
Davids MS, Burke J, Woyach JA, Shahkarami M, Eakle K, Ko J, Chopra V, Huang W, Farighi R, Ko RH, Sharman J, Wierda WG
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:45 PM
Duration 15mins Marriott Marquis San Diego Marina, San Diego Ballroom AB
Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma
Huntington S, Masaquel A, Ma E, Zuk E, Parise H, Davis M, Fox D, El Moustaid F, Ravelo A, Cassoli L, Wu M, Frosch Z
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 PM
Duration 15mins San Diego Convention Center, Ballroom 20AB
Fixed-duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-year Follow-Up From a Pivotal Phase II Study
Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Cartron G, Corradini P, Bartlett NL, Iacoboni G, Khan C, Hertzberg M, Falchi L, Brody J, Trněný M, Mulvihill E, Berthier A, Bottos A, Relf J, Bene Tchaleu F, Lundberg L, Hutchings M
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:30 AM
Duration 15mins San Diego Convention Center, Hall B
Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
Richter J, Thomas SK, Krishnan A, Laubach JP, Cohen AD, Trudel S, Costa LJ, Bahlis NJ, Forsberg PA, Kaedbey R, Fonseca R, Spencer A, Rodriguez-Otero P, Mateos M-V, Wong C, Cooper J, Tyagi T, Nakamura R, Choeurng V, Lesokhin A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 AM
Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
Glofitamab in Combination with Rituximab plus Ifosfamide, Carboplatin, and Etoposide shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-cell Therapy: Results from a Phase Ib Study
Diefenbach CS, Caimi P, Saba NS, Madueno FV, Hamadani M, Fayad LE, Riedell PA, Gillis-Smith A, Simko S, Orellana-Noia V, Filippou-Frye M, Kapp AV, Relf J, Lundberg L, Pinter-Brown LC
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:15 AM
Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-Up of a Phase Ib/II Study
Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jørgensen J, Zinzani PL, Gurion R, Goldschmidt N, Leung W, Li D, Relf J, Tandon M, Sellam G ,Gritti G
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 AM
Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Chavez JC, Olszewski AJ, Bastos-Orieo M, Assouline S, Lossos IS, Diefenbach C, Ghosh N, Modi D, Sabry W, Naik S, Shah NN, Foley R, Hodson D, Makadia S, Pham S, Penuel E, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Budde EL
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:45 AM
Duration 15mins Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
Englumafusp alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/r B-NHL: extended follow up analysis of the dose-escalation part of Phase 1 trial BP41072
Hutchings M, Dickinson M, Gritti G, Carlo-Stella C, Townsend W, Bosch F, Bartlett NL, Cartron G, Ghesquieres H, Houot R, Walter H, Offner F, Dimier N, Jamois C, Smith L, Herter S, Sahin D, Keelara A, Korfi K, Gallien J, Wasmer MH, Hinton H, Whayman M, Prieto I, Kazantzidis G, Lechner K, Morschhauser F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:00 AM
Duration 2hrs San Diego, USA
Biomarker correlates and clinical activity of cevostamab in patients with triple-class refractory multiple myeloma who have received >=1 prior B-cell maturation antigen-targeted bispecific antibody: results from the Phase I/II CAMMA 2 study
Delforge M, Richter J, Cohen YC, Corradini P, Sborov D, Lesokhin A, Berdeja J, Gatt M, Paris L,Rosinol L, Quach H, Kanwar M, Catalani O, Sewpaul P,Wassner-Fritsch E, Mishra A, Trunzer K, Kumar S
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Ravulizumab
Scheinberg P, Alzahrani H, Contento Gonzalo A, Höglund M, Kim JS, Panse J, Rose M, Schubert J, Ueda Y, Yap ES, Buri M, Compagno N, Gentile B, Sreckovic S, Kulasekararaj A
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Real-World Experience With Emicizumab for Hemophilia A From the Physician Perspective Based on Survey Data
Michael Recht, Hanna Salehi, Ella Morton, Chris Blazos, Sophie Lai, Lucy Lee, Juliana Biondo, Janet Lee
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Glofitamab with gemcitabine and oxaliplatin is cost-effective versus rituximab with gemcitabine and oxaliplatin for US patients with relapsed/refractory diffuse large B-cell lymphoma who were not candidates for autologous stem cell transplant
Fox D, El Moustaid F, Masaquel A, Rosettie KL, Celik H, Cassoli L, Flowers CR
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the Phase III STARGLO study
Gregory GP, Abramson J, Huang H-Q, Zhang Q-Y, Ku M, Yoon DH, Fox CP, Abdulhaq H, Townsend W, Ashby J, Harris A, Orellana-Noia V, Simko S, Kallemeijn M, Ta R, Relf J, Huang H, Lundberg L, Zhang H
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal Phase II study
Shadman M, Bartlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Ma CY, Tracy S, Kwan A, Penuel E, Budde LE
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
Al-Sawaf O, Locher B, Christen F, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Fustero C, Hablesreiter R, Seymour JF, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Eichhorst BF, Hallek MJ, Fischer K, Damm F
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon